URDANETA CITY

UNIVERSITY COLLEGE OF HEALTH SCIENCES

Owned and operated by the City Government of Urdaneta

DRUG STUDY
Name of Student: Fang, Marigel G___________________________________ Year Level and Group: BSN 4 Block 2_____________
Affiliating Agency/Area: Manaoag Community Hospital___________________ Month/Year of Exposure: March_________________

DRUG CLASSIFICATION INDICATION SIDE EFFECTS ADVERSE EFFECTS NURSING RESPONSIBILITIES

Generic Name:

Metoclopramide Dopamine receptor Medications used to treat  drowsiness Extrapyramidal disorders,

antagonist nausea and vomiting.  excessive tiredness drowsiness, headache,
Brand Name: vertigo, restlessness,
(Antiemetic)  weakness
Reglan weakness decreased level of
 headache
consciousness, anxiety,
Dosage:  dizziness
confusion, hallucination,
 diarrhea nausea, vomiting,
10 mg  nausea xerostomia, constipation,
Max: 30 mg or 0.5  vomiting hypotension and cardio-
mg/kg daily.  breast enlargement or respiratory arrest. Rarely,
discharge AV block.
Frequency:
 missed menstrual
TID period
 decreased sexual ability
Recommended max
 frequent urination
treatment duration: 5
 inability to control
days
urination

(075) 600 - 1507

Brightfuture starts here San Vicente West, Urdaneta City, Pangasinan
ucu.edu.ph | ucu.collegeofhealthsciences@gmail.com
 URDANETA CITY
UNIVERSITY
Owned and operated by the City Government of Urdaneta
MECHANISM OF
ACTION
Metoclopramide is a
substituted benzamide with
prokinetic and antiemetic
properties. It stimulates the
motility of the upper
gastrointestinal tract and
accelerates gastric
peristalsis without
stimulating gastric, biliary
or pancreatic secretions,
leading to increased gastric
emptying and intestinal
transit time. It blocks
dopamine receptors and
serotonin receptors (at
higher doses) in
chemoreceptor trigger zone
of the CNS.
Checked by: _________________________________
Clinical Instructor’s Name and Signature
Brightfuture starts here
COLLEGE OF HEALTH SCIENCES
CONTRAINDICATIONS
Patient with gastrointestinal This drug may cause drowsiness, dizziness, involuntary
perforation, haemorrhage or movements, if affected, do not drive or operate machinery.
mechanical obstruction,
suspected or known Monitor for signs and symptoms of tardive dyskinesia,
pheochromocytoma or other neuroleptic malignant syndrome, and extrapyramidal
catecholamine-releasing manifestations.
paragangliomas, history of
neuroleptic or drug-induced
tardive dyskinesia, seizure
disorder (e.g. epilepsy),
Parkinson’s disease, known
history of
methaemoglobinaemia with
metoclopramide or
nicotinamide adenine
dinucleotide-cytochrome b5
reductase (NADH-Cyb5R)
deficiency.
Date: ____________________
(075) 600 - 1507
San Vicente West, Urdaneta City, Pangasinan
ucu.edu.ph | ucu.collegeofhealthsciences@gmail.com